One study indicated that pharmacological inhibition of mammalian target of rapamycin (mTOR)/NLRP3 axis by rapamycin, alleviates the OSA-induced renal damage (Liu et al., 2022). The gene discussed is MTOR; the disease is obstructive sleep apnea syndrome.